Skip to main content

Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach

The European Journal of Health Economics volume 21, pages 321–334 (2020)Cite this article

Abstract

New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. The objectives of this article were to estimate the expected lifetime treatment cost of CRC for an average 70-year-old patient and to test the applicability and flexibility of a model in predicting survival and costs of changing treatment scenarios. The analyses were based on a validated semi-Markov model using data from a Norwegian observational study (2049 CRC patients) to estimate transition probabilities and the proportion resected. In addition, inputs from the Norwegian Patient Registry, guidelines, literature, and expert opinions were used to estimate resource use. We found that the expected lifetime treatment cost for a 70-year-old CRC patient was €47,300 (CRC stage I €26,630, II €38,130, III €56,800, and IV €69,890). Altered use of palliative chemotherapy would increase the costs by up to 29%. A 5% point reduction in recurrence rate for stages I–III would reduce the costs by 5.3% and increase overall survival by 8.2 months. Given the Norwegian willingness to pay threshold per QALY gained, society’s willingness to pay for interventions that could result in such a reduction was on average €28,540 per CRC patient. The life years gained by CRC treatment were 6.05 years. The overall CRC treatment costs appear to be low compared to the health gain, and the use of palliative chemotherapy can have a major impact on cost. The model was found to be flexible and applicable for estimating the cost and survival of several CRC treatment scenarios.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

Reproduced from [5] with kind permission from Sage publishers

Fig. 2

Reproduced from [5] with kind permission from Sage publishers

Availability of data and material

The Markov model and the data used are presented in a separate article (1). For modelling the Markov model, we used Excel 2016, and for the PSA we used @risk 7.5 for Excel from Palisade.

Abbreviations

5-FU/FA:

Nordic FLv = 5-fluorouracil/folinic acid

CI:

Confidence interval

COI:

Cost-of-illness

CRC:

Colorectal cancer

CrI:

Credible interval

EGFR-inh:

Epidermal growth factor receptor inhibitors (cetuximab/panitumumab)

FLIRI:

A combination of irinotecan and 5-fluorouracil/folinic acid

FLOX:

A combination of oxaliplatin and 5-FU/FA

FOBTs:

Faecal occult blood tests

HRQoL:

Health-related quality of life

LYs:

Life years

NPR:

National Patient Registry

OUS:

Oslo University Hospital

PSA:

Probabilistic sensitivity analysis

PS:

Patient performance status

QALY:

Quality-adjusted life years

WTP:

Willingness to pay

References

  1. Jemal, A., Center, M.M., DeSantis, C., Ward, E.M.: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomark. Prev. 19(8), 1893–1907 (2010)

    Article  Google Scholar 

  2. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W.W., Comber, H., et al.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374–1403 (2013)

    CAS  PubMed  Article  Google Scholar 

  3. Tarricone, R.: Cost-of-illness analysis. Health Policy 77(1), 51–63 (2006)

    PubMed  Article  Google Scholar 

  4. Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., et al.: budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17(1), 5–14 (2014)

    PubMed  Article  Google Scholar 

  5. Joranger, P., Nesbakken, A., Hoff, G., Sorbye, H., Oshaug, A., Aas, E.: Modeling and validating the cost and clinical pathway of colorectal cancer. Med. Decis. Mak. 35(2), 255–265 (2014). https://doi.org/10.1177/0272989X14544749

    Article  Google Scholar 

  6. Meltzer, D.: Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 16(1), 33–64 (1997)

    CAS  PubMed  Article  Google Scholar 

  7. Drummond, M., Sculpher, M., Torrance, G., O’Brien, B., Stoddart, G.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)

    Google Scholar 

  8. Sjo, O.H., Lunde, O.C., Nygaard, K., Sandvik, L., Nesbakken, A.: Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis. 10(1), 33–40 (2008)

    CAS  PubMed  Google Scholar 

  9. Nesbakken, A., Nygaard, K., Westerheim, O., Mala, T., Lunde, O.C.: Local recurrence after mesorectal excision for rectal cancer. Eur. J. Surg. Oncol. 28(2), 126–134 (2002)

    CAS  PubMed  Article  Google Scholar 

  10. Aas E (2009) Cost-effectiveness of screening for colorectal cancer with once-only flexible sigmoidoscopy and faecal occult blood test. In: Oslo University, Health Economics Research Programme

  11. Yabroff, K.R., Lawrence, W.F., Clauser, S., Davis, W.W., Brown, M.L.: Burden of illness in cancer survivors: findings from a population-based national sample. J. Natl. Cancer Inst. 96(17), 1322–1330 (2004). https://doi.org/10.1093/jnci/djh255

    PubMed  Article  Google Scholar 

  12. Saarni, S.I., Härkänen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., et al.: The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual. Life Res. 15(8), 1403–1414 (2006)

    PubMed  Article  Google Scholar 

  13. Do, Health: Economic evaluation of health intervention: a guide. The Norwegian Directorate of Health, Oslo (2012)

    Google Scholar 

  14. Mo, Finance: Guid for cost-benefit analysis. The Treasury Department, Oslo (2005)

    Google Scholar 

  15. Finance Mo: Principles and requirements for the preparation of socio-economic analyzes. Ministry of Finance, Oslo (2014)

    Google Scholar 

  16. Razenberg, L.G.E.M., Creemers, G.-J., Beerepoot, L.V., Vos, A.H., van de Wouw, A.J., Maas, H.A.A.M., et al.: Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta Oncol. 55(12), 1443–1449 (2016)

    PubMed  Article  Google Scholar 

  17. Sorbye, H., Pfeiffer, P., Cavalli-Björkman, N., Qvortrup, C., Holsen, M.H., Wentzel-Larsen, T., et al.: Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115(20), 4679–4687 (2009)

    PubMed  Article  Google Scholar 

  18. Scholefield, J.H., Moss, S.M., Mangham, C.M., Whynes, D.K., Hardcastle, J.D.: Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 61(7), 1036–1040 (2012)

    CAS  PubMed  Article  Google Scholar 

  19. RCPH (2007) Screening for colorectal cancer in Vejle and Copenhagen County: Research Centre for Prevention and Health (RCPH)

  20. Tappenden, P., Chilcott, J., Eggington, S., Sakai, H., Karnon, J., Patnick, J.: Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56(5), 677–684 (2007)

    PubMed  Article  Google Scholar 

  21. Frazier, A.L., Colditz, G.A., Fuchs, C.S., Kuntz, K.M.: Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284(15), 1954–1961 (2000)

    CAS  PubMed  Article  Google Scholar 

  22. Tappenden, P., Eggington, S., Nixon, R., Chilcott, J., Sakai, H., Karnon, J.: Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer. University of Sheffild, Sheffild (2004)

    Google Scholar 

  23. Ladabaum, U., Phillips, K.A.: Colorectal cancer screening: differential costs for younger versus older Americans. Am. J. Prev. Med. 30(5), 378–384 (2006)

    PubMed  Article  Google Scholar 

  24. Brown, M.L., Riley, G.F., Potosky, A.L., Etzioni, R.D.: Obtaining long-term disease specific costs of care: application to medicare enrollees diagnosed with colorectal cancer. Med. Care 37(12), 1249–1259 (1999)

    CAS  PubMed  Article  Google Scholar 

  25. Yabroff, K.R., Borowski, L., Lipscomb, J.: Economic studies in colorectal cancer: challenges in measuring and comparing costs. JNCI Monogr. 2013(46), 62–78 (2013)

    Article  Google Scholar 

  26. Tilson, L., Sharp, L., Usher, C., Walsh, C., Whyte, S., O’Ceilleachair, A., et al.: Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur. J. Health Econ. 13(4), 511–524 (2012)

    CAS  PubMed  Article  Google Scholar 

  27. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., et al.: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27(8), 1386–1422 (2016). https://doi.org/10.1093/annonc/mdw235

    PubMed  Article  Google Scholar 

  28. Tejpar, S., Stintzing, S., Ciardiello, F., et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 3(2), 194–201 (2017)

    PubMed  Article  Google Scholar 

  29. Norderhaug, I.T.H.: Pasientvolum og kvalitet ved koloncancerkirurgi. Nasjonalt kunnskapssenter for helsetjenesten, Oslo (2009)

    Google Scholar 

  30. Meyerhardt, J.A., Giovannucci, E.L., Holmes, M.D., Chan, A.T., Chan, J.A., Colditz, G.A., et al.: Physical activity and survival after colorectal cancer diagnosis. J. Clin. Oncol. 24(22), 3527–3534 (2006)

    PubMed  Article  Google Scholar 

  31. Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., et al.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24(22), 3535–3541 (2006)

    PubMed  Article  Google Scholar 

  32. Meyerhardt, J.A., Giovannucci, E.L., Ogino, S., Kirkner, G.J., Chan, A.T., Willett, W., et al.: Physical activity and male colorectal cancer survival. Arch. Intern. Med. 169(22), 2102–2108 (2009)

    PubMed  PubMed Central  Article  Google Scholar 

  33. Lynch, B.M., Cerin, E., Owen, N., Aitken, J.F.: Associations of leisure-time physical activity with quality of life in a large, population-based sample of colorectal cancer survivors. Cancer Causes Control 18(7), 735–742 (2007)

    PubMed  Article  Google Scholar 

  34. Haydon, A.M., MacInnis, R.J., English, D.R., Giles, G.G.: Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55(1), 62–67 (2006)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. Meyerhardt, J.A., Niedzwiecki, D., Hollis, D., Saltz, L.B., Hu, F.B., Mayer, R.J., et al.: Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 298(7), 754–764 (2007)

    CAS  PubMed  Article  Google Scholar 

  36. Huxley, R.R., Ansary-Moghaddam, A., Clifton, P., Czernichow, S., Parr, C.L., Woodward, M.: The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int. J. Cancer 125(1), 171–180 (2009)

    CAS  PubMed  Article  Google Scholar 

  37. Rock, C.L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K.S., Schwartz, A.L., et al.: Nutrition and physical activity guidelines for cancer survivors. CA Cancer J. Clin. 62(4), 242–274 (2012)

    Article  Google Scholar 

  38. Ravasco, P., Monteiro-Grillo, I., Camilo, M.: Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am. J. Clin. Nutr. 96(6), 1346–1353 (2012)

    CAS  PubMed  Article  Google Scholar 

  39. Hamers, P., Bos, A.C.R.K., May, A.M., Punt, C.J.A., Koopman, M., Vink, G.R.: Recent changes in overall survival of real-life stage IV colorectal cancer patients. J. Clin. Oncol. 37(15_suppl), 3522 (2019)

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge the Department of Health, Nutrition and Management (HEL), The Faculty of Health Sciences, and Oslo and Akershus University College of Applied Sciences for funding Paal Joranger’s doctorate.

Author information

Affiliations

  1. Norwegian University of Life Sciences, Ås, Norway

    Paal Joranger

  2. Faculty of Health Sciences, OsloMet-Oslo Metropolitan University, 0130, Oslo, Norway

    Paal Joranger & Arne Oshaug

  3. Department of Gastrointestinal Surgery, Oslo University Hospital, 0424, Oslo, Norway

    Arild Nesbakken

  4. K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424, Oslo, Norway

    Arild Nesbakken

  5. Faculty of Medicine, University of Oslo, Oslo, Norway

    Arild Nesbakken

  6. Department of Oncology and Department of Clinical Science, Haukeland University Hospital, Bergen, Norway

    Halfdan Sorbye

  7. University of Bergen, 5020, Bergen, Norway

    Halfdan Sorbye

  8. Telemark Hospital, Skien, Norway

    Geir Hoff

  9. The Cancer Registry of Norway, Oslo, Norway

    Geir Hoff

  10. University of Oslo, 0316, Oslo, Norway

    Geir Hoff

  11. Institute of Health and Society, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

    Eline Aas

Authors
  1. Paal Joranger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arild Nesbakken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Halfdan Sorbye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Geir Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arne Oshaug
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eline Aas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paal Joranger.

Ethics declarations

Conflict of interest

All authors contributed to the work, are aware of, and agree to the submission. Any other person or body with an interest in the manuscript, such as our funders and employers, are also aware and agreed on the submission. Paal Joranger, Eline Aas, and Arne Oshaug declare no support from any organisation for the submitted work, no financial relationships in the previous 3 years with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work. In 2017, Geir Hoff received payment from Amgen Norway for giving a lecture at a medical conference. Halfdan Sorbye received Grants and personal fees from Merck, Roche, and Amgen and personal fees from Sanofi during the study. Arild Nesbakken received funding from Helse Sør-Øst for the clinical studies on colorectal cancer (OUS-Aker series). He is a member of a research group in OUS, which has patents on one diagnostic and two prognostic genetic tests for colorectal cancer. He received payment from Amgen Norway for giving a lecture at a medical conference 2018. Financial support for this study was provided entirely by the authors’ employers, which are listed above. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the article. The authors declare that they have no competing interests.

Ethics approval and consent to participate

The observational study from 1993 to 2010, including 2049 patients diagnosed with CRC at Oslo University Hospital, was approved by the Regional Ethics Committee (Norway) for Medical Research (REK approval 1.2005.1629). The study with data collected from the National Patient Register (NPR) was approved by the Regional Ethics Committee (Norway). The reference number is S-02113 (2013/83).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Joranger, P., Nesbakken, A., Sorbye, H. et al. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. Eur J Health Econ 21, 321–334 (2020). https://doi.org/10.1007/s10198-019-01130-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-019-01130-6

Keywords

  • Colorectal cancer
  • Markov model
  • Cost
  • Surgery
  • Chemotherapy
  • Analyse innovations

JEL Classification

  • I110